JP2022554284A5 - - Google Patents
Info
- Publication number
- JP2022554284A5 JP2022554284A5 JP2022525329A JP2022525329A JP2022554284A5 JP 2022554284 A5 JP2022554284 A5 JP 2022554284A5 JP 2022525329 A JP2022525329 A JP 2022525329A JP 2022525329 A JP2022525329 A JP 2022525329A JP 2022554284 A5 JP2022554284 A5 JP 2022554284A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- genetically modified
- target
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928524P | 2019-10-31 | 2019-10-31 | |
| US62/928,524 | 2019-10-31 | ||
| PCT/US2020/058565 WO2021087466A1 (en) | 2019-10-31 | 2020-11-02 | Generation of cd38 knock-out primary and expanded human nk cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022554284A JP2022554284A (ja) | 2022-12-28 |
| JP2022554284A5 true JP2022554284A5 (enExample) | 2024-03-14 |
Family
ID=75715400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525329A Pending JP2022554284A (ja) | 2019-10-31 | 2020-11-02 | Ｃｄ３８ノックアウト初代および増殖ヒトｎｋ細胞の生成 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220401482A1 (enExample) |
| EP (1) | EP4051297A4 (enExample) |
| JP (1) | JP2022554284A (enExample) |
| KR (1) | KR20220093337A (enExample) |
| CN (1) | CN114867485A (enExample) |
| AU (1) | AU2020375053A1 (enExample) |
| BR (1) | BR112022008215A2 (enExample) |
| CA (1) | CA3156509A1 (enExample) |
| IL (1) | IL292584A (enExample) |
| MX (1) | MX2022005051A (enExample) |
| WO (1) | WO2021087466A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| EP4347816A4 (en) * | 2021-06-02 | 2026-04-29 | Metagenomi Therapeutics Inc | CRISPR CLASS II, TYPE V SYSTEMS |
| AU2022301302A1 (en) | 2021-07-01 | 2024-01-25 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| US20250302874A1 (en) * | 2021-11-03 | 2025-10-02 | Intellia Therapeutics, Inc. | Cd38 compositions and methods for immunotherapy |
| JP2025001053A (ja) * | 2021-11-05 | 2025-01-08 | 学校法人東海大学 | 劇症型ｎｋ白血病に対する治療標的の同定 |
| JP2025509343A (ja) | 2022-03-07 | 2025-04-11 | サノフィ－アベンティス・ユー・エス・エルエルシー | 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用 |
| CN114921416B (zh) * | 2022-05-12 | 2023-05-23 | 广东普罗凯融生物医药科技有限公司 | 一种nk细胞及其制备方法 |
| CN120051297A (zh) | 2022-06-30 | 2025-05-27 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法 |
| WO2024124244A1 (en) * | 2022-12-09 | 2024-06-13 | Research Institute At Nationwide Children's Hospital | Cd38 as integration site for enhanced function of gene-modified immune cells |
| WO2024124242A2 (en) * | 2022-12-09 | 2024-06-13 | Research Institute At Nationwide Children's Hospital | Combination cd38ko/car ki nk cell immunotherapy for dual targeting with cd38 monoclonal antibodies |
| WO2024155711A1 (en) * | 2023-01-17 | 2024-07-25 | Research Institute At Nationwide Children's Hospital | Methods of targeting glycogen synthase kinase 3 beta in nk cells |
| CN116679065B (zh) * | 2023-07-31 | 2023-11-14 | 北京大学人民医院 | 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品 |
| WO2025213127A1 (en) | 2024-04-05 | 2025-10-09 | Indapta Therapeutics, Inc. | Treatment of autoimmune diseases or conditions with natural killer cells |
| WO2025245399A1 (en) | 2024-05-23 | 2025-11-27 | Indapta Therapeutics, Inc. | Method of treating cancer with natural killer cells |
| WO2026050706A1 (en) * | 2024-08-30 | 2026-03-05 | Aventis Inc. | Nk cells having reduced cd38 expression and method for producing |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US128A (en) | 1837-02-16 | Holdback for sleds | ||
| FR1601438A (enExample) | 1968-10-17 | 1970-08-24 | ||
| CA2926078C (en) * | 2013-10-17 | 2021-11-16 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
| US10106620B2 (en) * | 2014-06-16 | 2018-10-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells |
| AU2015289644A1 (en) * | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| US10876134B2 (en) * | 2014-12-16 | 2020-12-29 | Board Of Regents Of The University Of Nebraska | Gene therapy for juvenile batten disease |
| EP3317399B1 (en) * | 2015-06-30 | 2024-06-26 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
| MA42895A (fr) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| EP3405568A4 (en) * | 2016-01-20 | 2019-12-04 | Fate Therapeutics, Inc. | COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
| CA3020330A1 (en) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| ES2875005T3 (es) * | 2016-12-09 | 2021-11-08 | Onk Therapeutics Ltd | Células asesinas naturales manipuladas y usos de las mismas |
| KR20250048610A (ko) * | 2017-12-22 | 2025-04-09 | 페이트 세러퓨틱스, 인코포레이티드 | 향상된 면역 효과기 세포 및 이의 용도 |
| CA3100341A1 (en) * | 2018-05-16 | 2019-11-21 | Research Institute Of Nationwide Children's Hospital | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins |
-
2020
- 2020-11-02 JP JP2022525329A patent/JP2022554284A/ja active Pending
- 2020-11-02 WO PCT/US2020/058565 patent/WO2021087466A1/en not_active Ceased
- 2020-11-02 IL IL292584A patent/IL292584A/en unknown
- 2020-11-02 KR KR1020227018144A patent/KR20220093337A/ko active Pending
- 2020-11-02 US US17/773,755 patent/US20220401482A1/en active Pending
- 2020-11-02 MX MX2022005051A patent/MX2022005051A/es unknown
- 2020-11-02 BR BR112022008215A patent/BR112022008215A2/pt unknown
- 2020-11-02 CN CN202080090071.9A patent/CN114867485A/zh active Pending
- 2020-11-02 AU AU2020375053A patent/AU2020375053A1/en active Pending
- 2020-11-02 EP EP20882013.4A patent/EP4051297A4/en active Pending
- 2020-11-02 CA CA3156509A patent/CA3156509A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Golomb et al. | p53 and ribosome biogenesis stress: the essentials | |
| Diorio et al. | Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks | |
| Van Vlierberghe et al. | The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia | |
| Ochoa et al. | Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells | |
| Walecki et al. | Androgen receptor modulates Foxp3 expression in CD4+ CD25+ Foxp3+ regulatory T-cells | |
| Katsogiannou et al. | The hallmarks of castration-resistant prostate cancers | |
| Cycon et al. | Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B‐cell lymphoma | |
| CN114867485A (zh) | Cd38敲除的原代和扩增的人nk细胞的生成 | |
| Vago et al. | Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia | |
| US20220062394A1 (en) | Methods for identifying neoantigens | |
| Testa et al. | CAR-T cell therapy in B-cell acute lymphoblastic leukemia | |
| WO2021043804A1 (en) | Immunotherapy targeting tumor neoantigenic peptides | |
| Gallouet et al. | Macrophage production and activation are dependent on TRIM33 | |
| Groza et al. | Recent advancements in the study of breast cancer exosomes as mediators of intratumoral communication | |
| Sakemura et al. | Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies | |
| WO2019191501A1 (en) | Use of histone modifiers to reprogram effector t cells | |
| JP2024513514A5 (enExample) | ||
| Kishimoto et al. | Molecular pathogenesis of follicular lymphoma | |
| JP2021516666A5 (enExample) | ||
| Petri et al. | Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities | |
| Chang et al. | Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system | |
| Konrad et al. | Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes | |
| EP4048304A1 (en) | Immunotherapy targeting tumor neoantigenic peptides | |
| Cheema et al. | Under the hood: evidence-based review of allogeneic chimeric antigen receptor t cells for hematologic malignancies | |
| Zak et al. | Positive and negative roles of myeloid cells in cancer immunotherapy |